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Abstract
Background: The use of neoadjuvant radiation therapy and chemotherapy in the treatment of locally advanced
rectal adenocarcinoma has been shown to reduce disease recurrence when combined with surgery and adjuvant
chemotherapy. We report a case of a patient who developed a debilitating bilateral myopathy of the hip flexors
after successful treatment for rectal cancer. To the best of our knowledge, this is the first such complication from
radiation therapy reported in a patient with colorectal cancer. The disproportionate severity of our patient’s
myopathy relative to the dose of radiation used also makes this case unique among reports of neuromuscular
complications from radiation therapy.
Case presentation: The patient is a 65-year-old male with node negative, high-grade adenocarcinoma of the
rectum penetrating through the distal rectal wall. He underwent neoadjuvant concurrent pelvic radiation therapy
and capecitabine-based chemotherapy, followed by abdominoperineal resection and post-operative FOLFOX
chemotherapy. Five months post-completion of pelvic radiotherapy and 2 months after the completion of adjuvant
chemotherapy, he presented with bilateral weakness of the iliopsoas muscles and severe pain radiating to the
groin. The patient improved with 40 mg/d of prednisone, which was gradually tapered to 2 mg/d over 6 months,
with substantial recovery of muscle strength and elimination of pain.
Conclusions: The timing, presentation and response of our patient’s symptoms to corticosteroids are most
consistent with a radiation recall reaction. Radiation recall is a phenomenon whereby previously irradiated tissue
becomes vulnerable to toxicity by subsequent systemic therapy and is rarely associated with myopathies. Radiation
recall should be considered a potential complication of neoadjuvant radiation therapy for rectal cancer, and for
ongoing research into the optimization of treatment for these patients. Severe myopathies caused by radiation
recall may be fully reversible with corticosteroid treatment.
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Background
Globally, colorectal cancer (CRC) is the third most com-
mon cause of cancer and the fourth leading cause of
cancer mortality [1]. Almost one-third of primary CRCs
are adenocarcinomas localized to the rectum between its
borders at the sigmoid colon and the dentate line.
Locally confined, low grade (T1-2) lesions (stage I) can
generally be treated with total mesorectal excision
(TME) surgery or even local excision, usually sparing the
anal sphincter. However, locally advanced T3-4 disease
penetrating through the wall of the rectum (stage II) or
involving local lymph nodes (stage III) requires aggres-
sive multimodal therapy.
For patients with stage II-III rectal adenocarcinoma,
the standard of practice in most of Europe and North
America involves three phases of treatment. Treatment
begins with a course of pre-operative (neoadjuvant)
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chemotherapy and radiation therapy (CRT), followed by
surgical resection of the tumour with sphincter-sparing
TME or non-sphincter-sparing surgery, most commonly
either a low anterior resection (LAR) or abdominoperi-
neal resection (APR), and post-operative (adjuvant)
chemotherapy. The addition of post-operative CRT to
surgical management dramatically reduced cancer recur-
rence and improved survival in patients with stage II-III
disease [2, 3]. Neoadjuvant CRT in conjunction with sur-
gery has been shown to confer a further reduction in
local disease recurrence and to delay recurrence com-
pared to adjuvant CRT with surgery [4, 5].
In this report, we present a patient who experienced a
rare complication following neoadjuvant CRT, surgery,
and adjuvant chemotherapy for locally invasive rectal
adenocarcinoma. During the adjuvant chemotherapy
phase of treatment, our patient developed a bilateral my-
opathy in his hip flexors that presented with sudden-on-
set severe pain and debilitating muscle weakness. His
condition was successfully managed with high-dose corti-
costeroids tapered over several months. The severity of
this case makes it unique among reports of neuromuscu-
lar complications from low doses of radiation therapy
(RT); furthermore, this is the first such case resulting from
neoadjuvant CRT for locally advanced rectal cancer.
Case presentation
A 65-year-old male was referred for investigation of a
rectal mass. The patient had a 2-year history of painless,
bright red bleeding per rectum. During this period he
had experienced increased fatigue and one bowel move-
ment per day with deformed, bloody stool. Apart from
having a polyp removed 1 year ago, he had no past med-
ical history or chronic medical conditions. The patient’s
father had prostate cancer and his mother had ovarian
cancer.
Digital rectal examination revealed an ulcerated mass
beginning at the anorectal junction, tethered along the
rectal canal to the overlying puborectalis muscle. A diag-
nosis of stage II (T3N0M0) invasive adenocarcinoma
was made on biopsy and imaging. Magnetic resonance
imaging (MRI) of the pelvis showed that the tumour was
located 4.5 cm above the anal verge and had an extra-
mural depth of invasion of 6 mm. It extended approxi-
mately 5.3 cm from the distal rectum along the right
side of the rectal canal. Coronal views suggested that the
mass penetrated the mesorectal fascia. Invasion of the
intersphincteric plane could not be excluded. There was
no involvement of adjacent lymph nodes or the periton-
eal reflection. Computed tomography (CT) of the abdo-
men and pelvis were negative for metastases.
Treatment consisted of three phases: (1) 5 weeks of
neoadjuvant CRT, (2) followed 4 weeks later by APR sur-
gery, and (3) 8 weeks of adjuvant chemotherapy. Pelvic
radiation with a total dose of 50 Gy was delivered in 25
fractions (5 days/week over 5 weeks) with a minimum of
10 mV photons. A six-field technique was used (anterior
oblique, oblique and posterior oblique fields bilaterally)
weighted higher in the right fields (Fig. 1). The max-
imum dose to the right femoral head was 4950 cGy
(mean 3482 cGy) compared to a maximum dose of
4705 cGy (mean 3173 cGy) to the left femoral head. In-
guinal nodes were included in the treatment based on the
low-lying location of the rectal lesion. Concurrent chemo-
therapy was administered with capecitabine (3300 mg/day
PO) delivered during radiation. Four weeks into neoadju-
vant treatment the patient developed hand-foot syndrome
so his dose of capecitabine was lowered. One week after
completion of CRT, the patient presented with painful,
red, ulcerating dermatitis on both sides of the groin with
desquamated skin overlying the penis and scrotum, as well
as perianal redness and excoriations, all of which healed
after management with flamazine and sitz baths. A repeat
MRI of the pelvis following neoadjuvant CRT showed that
the extent of the tumour along the rectal canal had been
reduced to 4.5 cm and the extramural depth of invasion
had been reduced to 4 mm.
Radical surgery consisted of APR with mesocortical
excision. Post-operative pathology confirmed the diagno-
sis of stage II (T3a) adenocarcinoma. Macroscopically, a
single polypoid mass was present with tumour-free mar-
gins and undamaged non-tumoural tissue. Microscopic
analysis of the tissue revealed a low grade tumour that
did not penetrate the rectal serosa. The smallest
tumour-free margin was 2.5 mm and no local node in-
vasion was found. Evidence of tumour response to neo-
adjuvant treatment was minimal and treatment-related
changes in the non-tumoural tissue were not described.
Fig. 1 Intensity-modulated radiation plan for pre-operative
chemoradiation treatment for locally advanced rectal cancer.
Axial image at the level of the proximal thigh. Inguinal nodes
were treated based on the low-lying location of the rectal lesion.
Radiation dose prescription = 5000 cGy. Isodose lines, red: 95 %,
purple: 80 %, beige: 50 %
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Following surgery, adjuvant FOLFOX chemotherapy
(5-fluoruracil, leucovorin, oxaliplatin) was delivered
IV for eight cycles.
Five months after the completion of pelvic radiother-
apy and 2 months after the completion of chemotherapy,
the patient presented with severe bilateral leg weakness
and pain that required hospitalization. The patient had a
5-week history of increasing, movement-aggravated pain
in the inguinal region that radiated to the thighs, and a
3-week history of worsening proximal muscle weakness
of the lower extremities. He assumed a stooped,
forward-flexed posture as this provided some pain relief.
On exam, the patient could only walk for a few steps.
There were palpable areas of fullness in the femoral tri-
angle, but no discrete lymphadenopathy. Motor power
was less than antigravity in the hip flexors bilaterally,
and was independent of pain. The patient was unable to
elevate his legs at the hip or flex them by more than 10°.
Femoral stretch and straight leg-raise tests severely ag-
gravated pain in the groin and anterior thighs. He had
full power in his hip extensors, knees and ankles. His
knee reflexes were decreased and ankle reflexes were ab-
sent. A CT scan of the pelvis was negative for abscesses.
His bone scan did not show abnormal involvement and
his MRI of the spine was not suggestive of a radiculopa-
thy or other spinal cord process. Creatine kinase (CK)
was within the normal range. The MRI of his pelvis ob-
tained 2 months after the completion of adjuvant
chemotherapy was remarkable for edema involving mul-
tiple muscle groups of the proximal thighs bilaterally,
consistent with an acute myopathic process (Fig. 2). An
electromyographic (EMG) study revealed moderate fib-
rillation potentials, positive sharp waves, and absent re-
cruitable motor units in the iliopsoas muscles, further
supporting a diagnosis of bilateral myopathy in this dis-
tribution. Needle examination of the abductor longus,
vastus medialis and tibialis anterior were unremarkable.
At the time of presentation, the patient was severely
debilitated and hospitalized for 3 weeks. His muscle
weakness and pain could only be controlled with a high
dose of prednisone (40 mg/d PO), which provided sub-
stantial symptom relief within 2–3 days. After discharge,
the patient was able to walk 4–5 short city blocks with-
out taking a break, but continued to experience some
pain at rest. Over the next 16 weeks prednisone was ta-
pered to 2 mg/d. This resulted in an increase in pain
and activity limitation over the first 6 weeks, but his
condition has been gradually improving since then with
reduced doses of prednisone. At last follow-up, he was
no longer experiencing pain and had grade 4+/5 power
in his hip flexors and grade 4/5 power in his hip adductors
bilaterally. He is expected to be weaned off prednisone
over the next few months.
Conclusions
We present the case of a patient who experienced a se-
vere myopathy following treatment for rectal adenocar-
cinoma. Shortly after the completion of adjuvant
chemotherapy, the patient presented with near-complete
functional limitation due to muscle weakness and severe
pain. His symptoms were localized to the thighs bilat-
erally, areas that received radiation during neoadjuvant
treatment, albeit in doses well within muscle tolerance.
Although the patient has yet to reach a complete func-
tional recovery, the strong response of both muscle weak-
ness and pain to gradually tapered doses of corticosteroids
is an encouraging sign that this complication of CRT is at
least partially reversible.
The cause of our patient’s symptoms is difficult to
pinpoint since multiple treatment modalities were used,
including RT and two different chemotherapy regimens.
Based on our review of comparable cases in the literature,
we considered two scenarios by which a myopathic
process could have been precipitated in our patient: (1)
as a delayed reaction to RT or (2) as a result of additive
effects of radiation and chemotherapy causing a radi-
ation recall reaction.
The location of myopathic changes in our patient sug-
gests that RT was a precipitating factor. Peripheral ner-
vous system dysfunction, plexopathies, myelopathies and
mononeuropathies are well-documented adverse events
following RT, with location and size of the radiation field
being pertinent risk factors [6]. Elderly patients or those
with poor overall health status have particularly poor out-
comes following extended-field RT compared to more
focal treatment [7]. RT-induced myopathy in the absence
of other neurological findings is extremely rare, most
commonly reported in patients with Hodgkin’s lymph-
omas treated with high-dose mantle field RT [8–12].
Ghosh and Milone recently published a large case series
describing 21 patients with radiation-induced myopathy,
Fig. 2 MRI pelvis post-radiation, axial STIR/T2W FSE sequence showing
edema of proximal leg muscles
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in which 13 patients were treated for Hodgkin’s lymph-
oma [9]. Almost half of the patients had severe neck pain
and muscle weakness causing head drop. Two patients
died during follow-up due to related hypercapnic respira-
tory failure. Similar to our patient, the majority of these
patients had myogenic changes on EMG with fibrillation
potentials, and near normal CK levels. Unlike our patient,
many of these patients had profound muscle atrophy and
muscle contractures, as well as associated neurogenic
findings on physical exam, EMG or imaging. Perhaps the
most notable discrepancy between previous reports of
radiation-induced myopathies and our case is the onset la-
tency of myopathic changes, typically occurring years or
decades after RT.
A second possible explanation is that chemotherapy
exacerbated tissue injury caused by RT in our patient.
Such a complication is known as radiation recall, a rare
phenomenon whereby previously irradiated tissue be-
comes vulnerable to toxicity by subsequent systemic
therapy [13]. Anti-cancer drugs are the most common
causes of radiation recall, but other precipitating agents
include antibiotics, anti-tuberculosis agents, and simva-
statin [14]. Radiation recall appears to be distinct from
radiosensitization, a much more common phenomenon
thought to last for up to 1 week after the completion of
RT. Radiation recall most commonly manifests as
dermatitis in previously irradiated skin [15], but it can
also manifest as myositis [16–19], enterocolitis [20], or
pneumonitis [21, 22].
There are several factors supporting radiation recall as
the cause of the complication seen in our patient. Al-
though a variety of anti-neoplastic drugs are associated
with radiation recall [14], anti-metabolites are among
the most common precipitating agents. This drug class
includes capecitabine and 5-fluorouracil (5-FU), both of
which were used to treat our patient. Consistent with
the presentation in our patient, radiation recall myositis
typically occurs within a few months of initiation of
chemotherapy and evidence of soft tissue edema on MRI
appears to be replicated finding [16–18]. Since any tissue
injury caused by RT in these patients remains subclinical
until the initiation of chemotherapy, high doses of RT
are not required to induce radiation recall. Indeed, a
comparable dose of RT (54 Gy, 28 fractions) was used in
a patient who developed a gemcitabine-induced myop-
athy of the rectus abdominus muscles 5 months after
CRT for pancreatic cancer [17]. Grover et al. recently de-
scribed a case in which a patient treated with RT, gemci-
tabine and carboplatin developed myositis in the left
shoulder and hip, with corresponding tissue edema on
MRI, 4 weeks after completion of RT [18]. Both foci of
this patient’s metastatic adenocarcinoma were treated
with lower total doses of 30 Gy in 10 fractions and the
myositis was relatively mild and self-limited. Severe
radiation recall myositis has been described in at least
one report of a 14-year-old girl who received neoadju-
vant CRT prior to surgery and post-operative gemcita-
bine for a synovial carcinoma of the forearm [16]. She
developed severe weakness, pain and tissue edema in her
forearm after the cessation of gemcitabine. This precipi-
tated a compartment syndrome that lasted for 1 year.
Interestingly, this case was also responsive to corticoste-
roids and gradually resolved with tapering. Other reports
suggest that the response of radiation recall to steroids
is variable [23], and withdrawal of the precipitating drug
may be enough to resolve mild myopathies [17, 18].
In summary, previous reports of radiation recall are
consistent with the onset, dose of RT, presentation
and response to treatment observed in our patient.
There are at least a couple of noteworthy cautions
regarding the interpretation of our findings. Firstly, a tis-
sue sample of the affected muscle in our patient was not
obtained, limiting our ability to compare this case with
previous biopsy-proven cases of radiation-induced my-
opathies [24]. However, the pathological analysis of our
surgical specimen revealed relatively preserved structural
integrity of the non-invaded tissues surrounding the
tumour. Since these undamaged tissues were focally irra-
diated, myonecrosis in the patient’s adjacent hip flexors
as a result of CRT would not be expected. Secondly, it is
possible that causes unrelated to radiation exposure
precipitated the myopathy in our patient. Myopathic
changes due to chemotherapy have been observed in the
context of oxaliplatin-induced peripheral neuropathies
[25] and capecitabine-associated dermatomyositis [26].
While our patient did develop peripheral neuropathy
during oxaliplatin-based (FOLFOX) adjuvant chemo-
therapy, this had a period of onset distinct from his
myopathy. A chemotherapy-only phenomenon in our
patient is unlikely due to the localized nature of our
findings corresponding to regions of previously irradi-
ated tissue.
We have presented a case of an extremely rare compli-
cation of RT that is notable both for its severity and
location of presentation. This is the first time that this
complication has been reported in a patient treated for
CRC. The use of neoadjuvant CRT in patients with
locally advanced rectal adenocarcinoma is a recently
adopted standard of care that has decreased the likeli-
hood of cancer recurrence in this patient population
[4, 5]. Our findings are particularly relevant in light of
the fact that optimization of CRT has been a focus of
recent and ongoing clinical trials [27–29]. 5-FU is the
most commonly used neoadjuvant chemotherapeutic
agent in this patient population. Capecitabine has
demonstrated similar efficacy to 5-FU and was chosen
for our patient due to the convenience of administra-
tion in its oral form [27, 28].
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So far, data from clinical trials have shown that neoadju-
vant CRT is well tolerated by patients with rectal cancer.
In patients receiving 5-FU-based CRT with 50.4 Gy of
total radiation, the most common acute complications
were dermatologic (27–40 %), diarrhea (12–18 %) and
hematologic (6–8 %) [4]. The most common long-term
complications were gastrointestinal (diarrhea, small bowel
obstruction; 9–15 %), strictures at the site of large bowel
anastomosis (4–12 %) and bladder dysfunction (2–4 %)
over 5 years of follow-up. Although these complications
are difficult to link directly to chemotherapy or radiother-
apy, the use of neoadjuvant CRT significantly reduced
both acute and chronic complications compared to adju-
vant CRT. Pre-operative administration of chemotherapy
and radiation thus appears to reduce toxicities related to
these treatments.
Our case report contributes to a growing body of data
for a complication of RT that remains poorly under-
stood. Although we cannot clearly ascertain whether our
patient’s symptoms were a direct result of RT or caused
by radiation recall, it is important to consider both com-
plications within the realm of possibilities in patients re-
ceiving the current 3-phase treatment for locally advanced
rectal cancer. Mild to moderate cases of radiation-induced
myopathy may be underreported due to loss of patients to
follow-up. Radiation recall may also be underreported,
particularly mild cases that disappear following withdrawal
of chemotherapy. Optimal doses of RT and chemotherapy
should continue to be sought in order to minimize com-
plications. It has been suggested that radiation recall can
be prevented by allowing a sufficient time interval be-
tween neoadjuvant RT and adjuvant chemotherapy [14];
however, at least one case of radiation recall was reported
21 years after RT, so the appropriate time interval may
vary on an individual basis [19]. While prevention of myo-
pathic complications in the cancer population may be
challenging so long as these phenomena remain poorly
understood, our report demonstrates encouraging evi-
dence of the effectiveness of corticosteroid treatment for
severe cases.
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